REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature

Shavali Shaik, Bridget Kennis, Shinji Maegawa, Keri Schadler, Yang Yanwen, Keri Callegari, Rishi R. Lulla, Stewart Goldman, Javad Nazarian, Veena Rajaram, Jason Fangusaro, Vidya Gopalakrishnan

Research output: Contribution to journalArticle

Abstract

Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive glial tumor that occurs in children. The extremely poor median and 5-year survival in children afflicted with DIPG highlights the need for novel biology-driven therapeutics. Here, we have implicated the chromatin remodeler and regulator of brain development called RE1 Silencing Transcription Factor (REST), in DIPG pathology. We show that REST protein is aberrantly elevated in at least 21% of DIPG tumors compared to normal controls. Its knockdown in DIPG cell lines diminished cell growth and decreased their tumorigenicity in mouse intracranial models. DIPGs are vascularized tumors and interestingly, REST loss in DIPG cells also caused a substantial decline in tumor vasculature as measured by a decrease in CD31 and VEGFR2 staining. These observations were validated in vitro, where a significant decline in tube formation by human umbilical vein endothelial cells (HUVEC) was seen following REST-loss in DIPG cells. Mechanistically, REST controlled the secretion of a pro-angiogenic molecule and ligand for VEGFR2 called Gremlin-1 (GREM-1), and was associated with enhanced AKT activation. Importantly, the decline in tube formation caused by REST loss could be rescued by addition of recombinant GREM-1, which also caused AKT activation in HUVECs and human brain microvascular endothelial cells (HBMECs). In summary, our study is the first to demonstrate autocrine and paracrine functions for REST in DIPG development. It also provides the foundation for future investigations on antiangiogenic therapies targeting GREM-1 in combination with drugs that target RESTassociated chromatin remodeling activities.

Original languageEnglish (US)
Pages (from-to)5233-5250
Number of pages18
JournalOncotarget
Volume9
Issue number4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Glioma
Up-Regulation
Brain Stem Neoplasms
Neoplasms
Chromatin Assembly and Disassembly
RE1-silencing transcription factor
Human Umbilical Vein Endothelial Cells
Brain
Drug Combinations
Neuroglia
Chromatin
Endothelial Cells
Pathology
Staining and Labeling
Ligands
Cell Line
Survival
Therapeutics
Growth
Proteins

Keywords

  • DIPG
  • Gremlin
  • REST
  • Vasculature
  • VEGFR2

ASJC Scopus subject areas

  • Oncology

Cite this

Shaik, S., Kennis, B., Maegawa, S., Schadler, K., Yanwen, Y., Callegari, K., ... Gopalakrishnan, V. (2018). REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. Oncotarget, 9(4), 5233-5250. https://doi.org/10.18632/oncotarget.23750

REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. / Shaik, Shavali; Kennis, Bridget; Maegawa, Shinji; Schadler, Keri; Yanwen, Yang; Callegari, Keri; Lulla, Rishi R.; Goldman, Stewart; Nazarian, Javad; Rajaram, Veena; Fangusaro, Jason; Gopalakrishnan, Vidya.

In: Oncotarget, Vol. 9, No. 4, 01.01.2018, p. 5233-5250.

Research output: Contribution to journalArticle

Shaik, S, Kennis, B, Maegawa, S, Schadler, K, Yanwen, Y, Callegari, K, Lulla, RR, Goldman, S, Nazarian, J, Rajaram, V, Fangusaro, J & Gopalakrishnan, V 2018, 'REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature', Oncotarget, vol. 9, no. 4, pp. 5233-5250. https://doi.org/10.18632/oncotarget.23750
Shaik S, Kennis B, Maegawa S, Schadler K, Yanwen Y, Callegari K et al. REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. Oncotarget. 2018 Jan 1;9(4):5233-5250. https://doi.org/10.18632/oncotarget.23750
Shaik, Shavali ; Kennis, Bridget ; Maegawa, Shinji ; Schadler, Keri ; Yanwen, Yang ; Callegari, Keri ; Lulla, Rishi R. ; Goldman, Stewart ; Nazarian, Javad ; Rajaram, Veena ; Fangusaro, Jason ; Gopalakrishnan, Vidya. / REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. In: Oncotarget. 2018 ; Vol. 9, No. 4. pp. 5233-5250.
@article{814c4e6d6f014c84bffa25784c67564a,
title = "REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature",
abstract = "Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive glial tumor that occurs in children. The extremely poor median and 5-year survival in children afflicted with DIPG highlights the need for novel biology-driven therapeutics. Here, we have implicated the chromatin remodeler and regulator of brain development called RE1 Silencing Transcription Factor (REST), in DIPG pathology. We show that REST protein is aberrantly elevated in at least 21{\%} of DIPG tumors compared to normal controls. Its knockdown in DIPG cell lines diminished cell growth and decreased their tumorigenicity in mouse intracranial models. DIPGs are vascularized tumors and interestingly, REST loss in DIPG cells also caused a substantial decline in tumor vasculature as measured by a decrease in CD31 and VEGFR2 staining. These observations were validated in vitro, where a significant decline in tube formation by human umbilical vein endothelial cells (HUVEC) was seen following REST-loss in DIPG cells. Mechanistically, REST controlled the secretion of a pro-angiogenic molecule and ligand for VEGFR2 called Gremlin-1 (GREM-1), and was associated with enhanced AKT activation. Importantly, the decline in tube formation caused by REST loss could be rescued by addition of recombinant GREM-1, which also caused AKT activation in HUVECs and human brain microvascular endothelial cells (HBMECs). In summary, our study is the first to demonstrate autocrine and paracrine functions for REST in DIPG development. It also provides the foundation for future investigations on antiangiogenic therapies targeting GREM-1 in combination with drugs that target RESTassociated chromatin remodeling activities.",
keywords = "DIPG, Gremlin, REST, Vasculature, VEGFR2",
author = "Shavali Shaik and Bridget Kennis and Shinji Maegawa and Keri Schadler and Yang Yanwen and Keri Callegari and Lulla, {Rishi R.} and Stewart Goldman and Javad Nazarian and Veena Rajaram and Jason Fangusaro and Vidya Gopalakrishnan",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23750",
language = "English (US)",
volume = "9",
pages = "5233--5250",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "4",

}

TY - JOUR

T1 - REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature

AU - Shaik, Shavali

AU - Kennis, Bridget

AU - Maegawa, Shinji

AU - Schadler, Keri

AU - Yanwen, Yang

AU - Callegari, Keri

AU - Lulla, Rishi R.

AU - Goldman, Stewart

AU - Nazarian, Javad

AU - Rajaram, Veena

AU - Fangusaro, Jason

AU - Gopalakrishnan, Vidya

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive glial tumor that occurs in children. The extremely poor median and 5-year survival in children afflicted with DIPG highlights the need for novel biology-driven therapeutics. Here, we have implicated the chromatin remodeler and regulator of brain development called RE1 Silencing Transcription Factor (REST), in DIPG pathology. We show that REST protein is aberrantly elevated in at least 21% of DIPG tumors compared to normal controls. Its knockdown in DIPG cell lines diminished cell growth and decreased their tumorigenicity in mouse intracranial models. DIPGs are vascularized tumors and interestingly, REST loss in DIPG cells also caused a substantial decline in tumor vasculature as measured by a decrease in CD31 and VEGFR2 staining. These observations were validated in vitro, where a significant decline in tube formation by human umbilical vein endothelial cells (HUVEC) was seen following REST-loss in DIPG cells. Mechanistically, REST controlled the secretion of a pro-angiogenic molecule and ligand for VEGFR2 called Gremlin-1 (GREM-1), and was associated with enhanced AKT activation. Importantly, the decline in tube formation caused by REST loss could be rescued by addition of recombinant GREM-1, which also caused AKT activation in HUVECs and human brain microvascular endothelial cells (HBMECs). In summary, our study is the first to demonstrate autocrine and paracrine functions for REST in DIPG development. It also provides the foundation for future investigations on antiangiogenic therapies targeting GREM-1 in combination with drugs that target RESTassociated chromatin remodeling activities.

AB - Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive glial tumor that occurs in children. The extremely poor median and 5-year survival in children afflicted with DIPG highlights the need for novel biology-driven therapeutics. Here, we have implicated the chromatin remodeler and regulator of brain development called RE1 Silencing Transcription Factor (REST), in DIPG pathology. We show that REST protein is aberrantly elevated in at least 21% of DIPG tumors compared to normal controls. Its knockdown in DIPG cell lines diminished cell growth and decreased their tumorigenicity in mouse intracranial models. DIPGs are vascularized tumors and interestingly, REST loss in DIPG cells also caused a substantial decline in tumor vasculature as measured by a decrease in CD31 and VEGFR2 staining. These observations were validated in vitro, where a significant decline in tube formation by human umbilical vein endothelial cells (HUVEC) was seen following REST-loss in DIPG cells. Mechanistically, REST controlled the secretion of a pro-angiogenic molecule and ligand for VEGFR2 called Gremlin-1 (GREM-1), and was associated with enhanced AKT activation. Importantly, the decline in tube formation caused by REST loss could be rescued by addition of recombinant GREM-1, which also caused AKT activation in HUVECs and human brain microvascular endothelial cells (HBMECs). In summary, our study is the first to demonstrate autocrine and paracrine functions for REST in DIPG development. It also provides the foundation for future investigations on antiangiogenic therapies targeting GREM-1 in combination with drugs that target RESTassociated chromatin remodeling activities.

KW - DIPG

KW - Gremlin

KW - REST

KW - Vasculature

KW - VEGFR2

UR - http://www.scopus.com/inward/record.url?scp=85040441694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040441694&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23750

DO - 10.18632/oncotarget.23750

M3 - Article

VL - 9

SP - 5233

EP - 5250

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 4

ER -